CULLINAN THERAPEUTICS INC (CGEM)
Sector: Health Care
2026 Annual Meeting Analysis
CULLINAN THERAPEUTICS INC · Meeting: June 16, 2026
Directors FOR
2
Directors AGAINST
0
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Class III Directors
Ahmed has served since October 2021 (approximately 4.5 years); the stock's 3-year price return of +20.2% trails the XBI — SPDR S&P Biotech ETF by 45.1 percentage points, but the applicable threshold for a company with strong positive TSR (above +20%) requires a gap of at least 65 percentage points before triggering a vote against, so the TSR trigger does not fire; no overboarding, attendance, or independence concerns apply.
Webster has served since September 2020 (approximately 5.5 years); the stock's 3-year return of +20.2% trails XBI — SPDR S&P Biotech ETF by 45.1 percentage points, which falls short of the 65-percentage-point threshold required to trigger a vote against for companies with strong positive absolute TSR; he holds one outside public board seat (NextCure), well below the four-board overboarding limit, and he attended at least 75% of meetings in 2025.
Both Class III director nominees — CEO Nadim Ahmed and independent director Stephen Webster — pass all policy screens. The company's 3-year stock return of +20.2% lags the XBI — SPDR S&P Biotech ETF by 45.1 percentage points, but because the absolute return is in the strong-positive tier (above +20%), the underperformance threshold is 65 percentage points, which is not met. No overboarding, attendance, independence, or family-relationship concerns exist for either nominee.
Say on Pay
✓ FORCEO
Nadim Ahmed
Total Comp
$5,100,006
Prior Support
N/A
CEO Nadim Ahmed's total reported compensation of $5,100,006 for 2025 is a meaningful reduction from $7,684,366 in 2024, reflecting lower equity grant values, which is consistent with pay-for-performance alignment as the stock declined during the year. Pay mix is appropriate: base salary of $698,476 represents approximately 14% of total compensation, with the remainder in variable equity and bonus components, well exceeding the 50-60% variable pay threshold the policy requires. The company has a clawback policy overseen by the compensation committee, annual bonuses are tied to pre-defined corporate performance metrics, and no prior-year say-on-pay support concern is flagged in the filing.
Auditor Ratification
✓ FORAuditor
KPMG LLP
Tenure
8 yrs
Audit Fees
$899,000
Non-Audit Fees
$202,468
Non-audit fees (tax services of $202,468) represent approximately 22.5% of audit fees ($899,000), well below the 50% threshold that would raise independence concerns; KPMG has served since 2018 (approximately 8 years), far below the 25-year tenure trigger; no material restatements are disclosed; and KPMG is a Big 4 firm appropriate for a company of this size and complexity.
Overall Assessment
The 2026 Cullinan Therapeutics annual meeting presents three straightforward proposals — director elections, auditor ratification, and an advisory pay vote — all of which pass policy screens and receive FOR votes. No stockholder proposals appear on the ballot, no overboarding or independence concerns exist among the director nominees, KPMG's non-audit fee ratio is well within acceptable limits, and executive compensation reflects a pay structure that is predominantly variable and directionally responsive to company performance.